Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China
Objectives: To report the perioperative management experience of central venous access devices (CVAD) in Chinese children with severe hemophilia A (SHA) in China. Methods: This retrospective study included SHA children who underwent Port-A-Cath or peripherally inserted central catheter (PICC) implan...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | Heliyon |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405844023008733 |
| _version_ | 1797851952408690688 |
|---|---|
| author | Qian Xu Chunli Wang Wei Cheng Yingzi Zhen Yaguang Ding Guoqing Liu Wanru Yao Zhenping Chen Zhiqiang Li Runhui Wu |
| author_facet | Qian Xu Chunli Wang Wei Cheng Yingzi Zhen Yaguang Ding Guoqing Liu Wanru Yao Zhenping Chen Zhiqiang Li Runhui Wu |
| author_sort | Qian Xu |
| collection | DOAJ |
| description | Objectives: To report the perioperative management experience of central venous access devices (CVAD) in Chinese children with severe hemophilia A (SHA) in China. Methods: This retrospective study included SHA children who underwent Port-A-Cath or peripherally inserted central catheter (PICC) implantation between 2020/01 and 2021/07. Collected data included baseline characteristics, factor replacement regimen and CVAD-related complications. Results: Nine patients had nine ports placed, and eight patients underwent 10 PICCs placement. Patients without or with low-titer inhibitor (<5 BU) received a port. The median preoperative and postoperative plasma-derived factor VIII (pd-FVIII) doses were 53.0 (44.4–61.1) and 315.9 (88.2–577.8) IU/kg. The median port duration was 189 (15–512) days, with infection incidence of 0.06 per 1000 CVAD days. Patients with high-titer inhibitors (>10 BU) received PICC. The median recombinant factor VIIa (rFVIIa) dose was 87.47 μg/kg before and for 5–7 doses after implantation over 2–3 days. The median PICC duration was 226.5 days, with infection incidence of 0.12 per 1000 catheter-days. Conclusions: CVADs can be safely implanted in China. PICC implantation is a practical and safe option for SHA children with high-titer inhibitors. |
| first_indexed | 2024-04-09T19:26:11Z |
| format | Article |
| id | doaj.art-f9ee3ab72fa348b79736bfcd7bd48efb |
| institution | Directory Open Access Journal |
| issn | 2405-8440 |
| language | English |
| last_indexed | 2024-04-09T19:26:11Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Heliyon |
| spelling | doaj.art-f9ee3ab72fa348b79736bfcd7bd48efb2023-04-05T08:15:48ZengElsevierHeliyon2405-84402023-03-0193e13666Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of ChinaQian Xu0Chunli Wang1Wei Cheng2Yingzi Zhen3Yaguang Ding4Guoqing Liu5Wanru Yao6Zhenping Chen7Zhiqiang Li8Runhui Wu9Department II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China; Department of Hematology & Oncology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 611731, ChinaNursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, ChinaDepartment of Cardiovascular Surgery II, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, ChinaNursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, ChinaNursing Department, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, ChinaDepartment II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, ChinaDepartment II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, ChinaDepartment II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, ChinaDepartment of Cardiovascular Surgery II, Beijing Children's Hospital, Capital Medical University; National Center for Children's Health, Beijing 100045, ChinaDepartment II of Hematology Center, Haemophilia Comprehensive Care Center, Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, Beijing 100045, China; Hematology Center, Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing 100045, China; Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China; National Key Discipline of Pediatrics, Capital Medical University, Beijing 100045, China; Corresponding author. 56 Nanlishi Rd, Beijing 100045, China.Objectives: To report the perioperative management experience of central venous access devices (CVAD) in Chinese children with severe hemophilia A (SHA) in China. Methods: This retrospective study included SHA children who underwent Port-A-Cath or peripherally inserted central catheter (PICC) implantation between 2020/01 and 2021/07. Collected data included baseline characteristics, factor replacement regimen and CVAD-related complications. Results: Nine patients had nine ports placed, and eight patients underwent 10 PICCs placement. Patients without or with low-titer inhibitor (<5 BU) received a port. The median preoperative and postoperative plasma-derived factor VIII (pd-FVIII) doses were 53.0 (44.4–61.1) and 315.9 (88.2–577.8) IU/kg. The median port duration was 189 (15–512) days, with infection incidence of 0.06 per 1000 CVAD days. Patients with high-titer inhibitors (>10 BU) received PICC. The median recombinant factor VIIa (rFVIIa) dose was 87.47 μg/kg before and for 5–7 doses after implantation over 2–3 days. The median PICC duration was 226.5 days, with infection incidence of 0.12 per 1000 catheter-days. Conclusions: CVADs can be safely implanted in China. PICC implantation is a practical and safe option for SHA children with high-titer inhibitors.http://www.sciencedirect.com/science/article/pii/S2405844023008733Hemophilia AChildrenVascular access devicesPort-A-CathPeripherally inserted central catheterFactor replacement regimen |
| spellingShingle | Qian Xu Chunli Wang Wei Cheng Yingzi Zhen Yaguang Ding Guoqing Liu Wanru Yao Zhenping Chen Zhiqiang Li Runhui Wu Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China Heliyon Hemophilia A Children Vascular access devices Port-A-Cath Peripherally inserted central catheter Factor replacement regimen |
| title | Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China |
| title_full | Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China |
| title_fullStr | Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China |
| title_full_unstemmed | Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China |
| title_short | Central venous access devices implantation in children with severe hemophilia a: data from the children comprehensive care center of China |
| title_sort | central venous access devices implantation in children with severe hemophilia a data from the children comprehensive care center of china |
| topic | Hemophilia A Children Vascular access devices Port-A-Cath Peripherally inserted central catheter Factor replacement regimen |
| url | http://www.sciencedirect.com/science/article/pii/S2405844023008733 |
| work_keys_str_mv | AT qianxu centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT chunliwang centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT weicheng centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT yingzizhen centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT yaguangding centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT guoqingliu centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT wanruyao centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT zhenpingchen centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT zhiqiangli centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina AT runhuiwu centralvenousaccessdevicesimplantationinchildrenwithseverehemophiliaadatafromthechildrencomprehensivecarecenterofchina |